Albert David Limited (ALBERTDAVD)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹697.25 ↓ 24.37% (1Y)

🎯 Key Takeaways

Albert David Limited is currently in a turnaround phase marked by deteriorating profitability and declining investor confidence, as evidenced by a 24.37% one-year return and widening net losses.
⚠️ Persistent net loss expansion with no visible path to profitability improvement.

Market Cap

₹411

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About ALBERTDAVD 📊 Interactive Charts

📖 The Story

Albert David Limited is currently in a turnaround phase marked by deteriorating profitability and declining investor confidence, as evidenced by a 24.37% one-year return and widening net losses. The company has experienced a significant year-on-year deterioration in financial performance, with Q4 FY2026 reporting a net loss of ₹2,143.44 lakhs compared to ₹149.47 lakhs in the same quarter last year. Management has not provided forward guidance, and recent regulatory filings highlight governance and credit concerns rather than strategic momentum.

📰 What's Happening

In Q4 FY2026, the company reported a sharp rise in net loss to ₹2,143.44 lakhs from ₹149.47 lakhs YoY, with total comprehensive income loss increasing to ₹1,906.54 lakhs. The board meeting on May 12, 2026, approved these results, which were filed on May 13, 2026. A subsequent insider trading compliance filing on June 23, 2026, announced a trading window closure until 48 hours after unaudited Q1 results are declared. Additionally, on May 29, 2026, Mr. Chandra Bhushan Thakur, Head of Operations at the Ghaziabad plant, resigned due to personal reasons, as disclosed in a SEBI LODR Regulation 30 filing. Credit rating agency CARE also downgraded the company's bank facilities to CARE A with a Negative outlook, reducing long-term facilities to ₹50.50 crores and short-term facilities to ₹12.00 crores.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on profitability, revenue growth, or margin improvement in the available filings. The most recent disclosures focus on compliance and administrative matters rather than strategic outlook. The upcoming unaudited Q1 results, whose declaration will trigger the reopening of the trading window, may offer early signals of performance trends, but no guidance has been issued on expected outcomes or timelines for recovery.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Persistent net loss expansion with no visible path to profitability improvement. 2. Downgrade of bank facilities by CARE Ratings with a Negative outlook, signaling weakened financial performance and increased credit risk. 3. Resignation of key operational leadership at the Ghaziabad plant, potentially affecting execution continuity. 4. Lack of forward guidance from management, creating uncertainty around strategic direction and recovery timeline.

📋 Recent Filings

🧠 Analyst's Read

Albert David Limited is navigating a challenging phase characterized by deteriorating financial results, credit rating pressure, and leadership change, with no clear indication of a turnaround strategy. Investors should monitor upcoming unaudited Q1 results for early signals of operational improvement and await potential management commentary on restructuring or cost initiatives. The absence of guidance and ongoing credit concerns warrant caution, though no immediate triggers for recovery have been announced.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ALBERTDAVD

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when ALBERTDAVD files new disclosures

Track ALBERTDAVD filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ALBERTDAVD — Free

Free account · 2 AI queries/day